INTRODUCTION
Regulating protein stability using small molecules provides a rapid, reversible, and tunable method to study a protein of interest's (POI) role in cells. We recently designed a small protein domain based on the 12-kDa FKBP (FK506 binding protein) that can be fused at either the carboxyl or amino terminus of a protein of interest. This destabilization domain (DD) confers instability to fusion protein partners. The method described here explains how to use a DD fusion to control the biological activity of a POI. In the absence of a small molecule ligand, the DD is unstable and directs the fusion protein for degradation. Addition of the ligand stabilizes the DD, allowing the fusion protein to accumulate in cells and the POI to exert its biological effect. The ligand is specific for the DD and has no detectable off-target effects. By utilizing the specificity of genetic fusion and the speed of small molecule binding, this technique provides an alternative to RNA interference to study a POI's role in cells.
RELATED INFORMATION
A schematic representation of the theory underlying this procedure is presented in Figure 1 . This protocol can be used in conjunction with A General Method for Conditional Regulation of Protein Stability in Living Animals . A number of commercially available systems (ProteoTuner, Clontech) include the Shield-1 ligand and DD vectors in plasmid, retroviral, and lentiviral formats, and allow for selection by antibiotic resistance and/or fluorescence. Shield-1 can also be purchased through Cheminpharma.
View larger version (12K):
[in this window] Figure 1 . Genetic fusion of the DD to a POI confers instability to the entire fusion product, resulting in protein degradation. Addition of a small molecule ligand (e.g., Shield-1) rescues the fusion and allows the POI to exert its normal biological effect.
[in a new window]
MATERIALS Reagents
Antibiotic (e.g., G418, puromycin) (optional; see
Step 13.i) 7. The following evening (i.e., Day 3), plate 1 x 10 6 NIH/3T3 cells per 10-cm plate to be infected.
For other cell lines, plate at a cell density such that the cells are ~30%-40% confluent at the time of infection.
8. Forty-eight hours after transfection (i.e., Day 4), harvest the viral particles by filtering the medium from the Phoenix cells through a 0.45-m syringe filter.
9. Add polybrene to a final concentration of 4 g/mL to the viral particle suspension.
Proceed immediately to creation of the cell line (Step 11).
Alternatively, the viral supernatant can be frozen and stored at -80°C. However, freezing viral supernatants reduces the viral titer by ~50%.
Cell Line Creation
11. Aspirate the medium from the NIH/3T3 cells. Add 3 mL of filtered viral supernatant to each dish.
The remaining supernatant can be frozen at -80°C for later use.
12. Four hours after infection, replace the viral medium with 10 mL of medium for 3T3 cells. See Troubleshooting.
For drug selection:
i. Grow cells under selection for at least 7 d.
For flow cytometric selection using a fluorescent marker:
ii. Sort a number of cells sufficient for use in downstream experiments. 17. To more fully characterize the DD-POI fusion, perform a dose-response curve with Shield-1 (1 nM to 3 M):
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i. Measure the half maximal effective concentration (EC 50 ) and maximum stabilization.
ii. Assay stabilization kinetics with growth and decay time courses after addition and removal of drug, respectively.
Dose cells with Shield-1 simply by adding the drug to the medium. Remove Shield-1 by washing the cells three times with fresh medium. For additional information on kinetics
experiments, see Banaszynski et al. (2006) .
TROUBLESHOOTING Problem:
Low infection is observed when creating cell lines.
[
Step 13] Solution:
1. Verify that polybrene was added to the viral supernatant before infection. Polybrene is a cationic lipid that helps diminish the electrostatic repulsion of the viral particle with the cell surface, thus aiding binding.
2. Try concentrating the viral supernatant with a 100,000 MWCO Amicon spin concentrator before adding polybrene. Concentrating the sample from 10 mL to 3 mL increases the viral titer.
3. Cleaning up and concentrating the vector DNA with a Midi-or Maxi-Prep can increase the efficiency of the lipofection (Step 5). Ideally, the DNA concentration should be at least 800 ng/ L.
Problem:
No signal for drug-dependent stabilization of the DD-POI fusion is detected by protein blotting.
[Step 16]
Solution: The POI might not tolerate a fusion on that terminus of the protein. Try changing the fusion protein to place the DD at the other terminus of the POI. A linker is not usually necessary, but could help the POI fold properly. Using the F36V domain as a stable control can help identify if the DD-POI fusion is properly expressed.
Problem:
The fusion protein is not destabilized.
[Step 16]
Solution: Moving the DD to the other terminus of the POI can change fusion protein stability. However, this technique has not been validated for every single protein; it is possible some proteins are not amenable to the DD system. Note that E31G R71G K105E is a more effective destabilizer than L106P at the C terminus of proteins.
DISCUSSION
Modulating a protein of interest's stability with a DD provides the user with unparalleled control of protein function. This technique is faster than RNA interference, reversible and tunable (unlike the Cre/lox system), and more specific than most chemical perturbants (Banaszynski et al. 2006; Maynard-Smith et al. 2007) .
Notably, addition of 1 M Shield-1 has no detectable off-target effects, as judged by microarray (Maynard-Smith et al. 2007 ). To date, this system has successfully regulated examples of intracellular, nuclear, and secreted proteins . However, it is unlikely that this technology will work for every protein in a cell. The POI might lose its functionality when fused, especially if its active state is part of a higher-order multimer. The DD placement, however, is very flexible. DDs have been shown to work at both termini, as well as in an internal loop of the POI (Chu et al. 2008 Anyone using the procedures outlined in these protocols does so at their own risk. Cold Spring Harbor Laboratory makes no representations or warranties with respect to the material set forth in these protocols and has no liability in connection with their use. All materials used in these protocols, but not limited to those highlighted with the Warning icon, may be considered hazardous and should be used with caution. For a full listing of cautions, click here.
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